Volume 11, Number 11—November 2005
Staphylococcus aureus Bacteremia, Europe
Highlight and copy the desired format.
|EID||Tiemersma EW, Monnet DL, Bruinsma N, Skov R, Monen J, Grundmann H, et al. Staphylococcus aureus Bacteremia, Europe. Emerg Infect Dis. 2005;11(11):1798-1799. https://dx.doi.org/10.3201/eid1111.050524|
|AMA||Tiemersma EW, Monnet DL, Bruinsma N, et al. Staphylococcus aureus Bacteremia, Europe. Emerging Infectious Diseases. 2005;11(11):1798-1799. doi:10.3201/eid1111.050524.|
|APA||Tiemersma, E. W., Monnet, D. L., Bruinsma, N., Skov, R., Monen, J., & Grundmann, H. (2005). Staphylococcus aureus Bacteremia, Europe. Emerging Infectious Diseases, 11(11), 1798-1799. https://dx.doi.org/10.3201/eid1111.050524.|
To the Editor: In their article, Collignon et al. (1) present a table comparing absolute numbers and incidence rates of Staphylococcus aureus bacteremia (SAB) in Australia to those of 5 other countries, and state that "some data are available from other countries for comparison" and "only 2 countries, Denmark and England, appeared to have comprehensive collection systems."
We would like to add data from the European Antimicrobial Resistance Surveillance System (EARSS) to their table. EARSS is a multinational surveillance system that links national networks by collecting comparable and validated data on the prevalence of antimicrobial resistance of 5 microorganisms, including S. aureus (2). A total of 30 countries participate in EARSS. To ensure representativeness of the data it publishes, EARSS has set criteria, which can be found elsewhere (3).
In 2003, through a questionnaire, we collected background information on all hospitals served by laboratories participating in EARSS, including the estimated hospitals' catchment populations. Proportion of the country population covered by EARSS was then calculated by dividing the sum of catchment populations by the total population of the country (4). Catchment populations of hospitals providing single specialty or supra-regional type of care were not counted to avoid overlap with other hospitals within the same country. Only the countries that provided denominator data for at least 60% of the isolates were included to ensure that the sample of hospitals was still representative of the country as a whole.
The number of SAB and the incidence of SAB per 100,000 inhabitants in 2003 were calculated from EARSS data, adjusted for population coverage, and are presented in the Table. These are crude estimates of the true number of SAB and should, thus, be interpreted with caution. For example, we assumed that the isolates for which hospital background information was not available did not differ from isolates for which we had this information, and that hospitals that participated in EARSS in 2003 were a representative sample of the countries' hospitals. Additionally, the incidence of SAB was positively correlated with the blood culturing rate (Spearman r = 0.74, p = 0.002), which means that the incidence of SAB is likely to have been underestimated in countries that reported few blood cultures. Although some countries did not report their blood culturing rate, the incidences of SAB in these countries were among the highest and are unlikely to be underestimated. For example, the EARSS data for Denmark and Ireland nicely fitted those presented in Table 4 of the article by Collignon et al. (1). Finally, reporting to the EARSS system greatly improved over the years, which is why this study was performed on the last available year, 2003. Nevertheless, one cannot exclude underreporting of SAB by EARSS participating hospitals since EARSS is a voluntary reporting system. For example, England reported 18,403 SAB cases or an incidence of 37 SAB per 100,000 inhabitants from April 2002 to March 2003 through its mandatory surveillance scheme (5), whereas an estimate for the United Kingdom from the EARSS database would only give 7,800 SAB cases for 2003. However, it is impossible to determine whether this discrepancy was due to poor voluntary reporting of SAB cases, a lower blood culturing rate in EARSS participating hospitals, or a poorly representative sample of the country's hospitals. Data from the United Kingdom were excluded from the present study on the basis of the latter possibility; denominator information for <60% of the isolates was available.
In conclusion, EARSS is the first comprehensive surveillance system on antimicrobial resistance in Europe. Within certain limitations, EARSS can also provide valuable information on blood-culturing practices and the incidence of SAB in Europe. The system is continuously being improved, and additional information on the representativeness of EARSS data is being collected. This will allow us to improve the quality and accuracy of the reported incidence rates. In the future, the system should allow reporting of similar data for an even larger number of European countries and for additional microorganisms, such as Escherichia coli.
- Collignon P, Nimmo GR, Gottlieb T, Gosbell IB. Australian Group on Antimicrobial Resistance. Staphylococcus aureus bacteremia, Australia. Emerg Infect Dis. 2005;11:554–61.
- Tiemersma EW, Bronzwaer SL, Lyytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N, Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10:1627–34.
- European Antimicrobial Resistance Surveillance System. EARSS manual 2004 [cited 2005 July 25]. Available from http://www.earss.rivm.nl
- Central Intelligence Agency. The world fact book 2003 [cited 2005 July 26]. Available from http://www.cia.gov/cia/download2003.htm
- Health Protection Agency. The second year of the Department of Health's mandatory MRSA bacteraemia surveillance scheme in acute trusts in England: April 2002–March 2003. CDR Weekly. 2003;13:1–9. [cited 2005 July 26]. Available from http://www.hpa.org.uk/cdr/archives/2003/cdr2503.pdf
- Table. Absolute numbers, rates of Staphylococcus aureus bacteremia (SAB), and percentage of methicillin-resistant Staphylococcus aureus (MRSA), European Antimicrobial Resistance Surveillance System (EARSS), 2003
Please use the form below to submit correspondence to the authors or contact them at the following address:
Edine Tiemersma, National Institute for Public Health and the Environment, Center for Infectious Diseases Epidemiology, PO Box 1, Bilthoven 3720, the Netherlands; fax: 31-30-274-44-09Edine Tiemersma, National Institute for Public Health and the Environment, Center for Infectious Diseases Epidemiology, PO Box 1, Bilthoven 3720, the Netherlands; fax: 31-30-274-44-09
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: February 17, 2012
- Page last updated: February 17, 2012
- Page last reviewed: February 17, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)